INSTITUTO INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ

Their core work

IIS-FJD is a clinical research institute embedded within the Fundación Jiménez Díaz hospital in Madrid, specializing in translational cardiovascular and oncology research. They bridge laboratory science and patient care, running clinical trials in areas like cardio-oncology (protecting hearts from cancer treatment damage), rare disease gene therapy, and precision medicine for aggressive lymphomas. Their work focuses on turning molecular-level insights into bedside tools — risk prediction models, drug repurposing strategies, and targeted therapies for conditions where standard treatment options fall short.

What they specialise in

How they've shifted over time

In the early period (2015–2019), IIS-FJD worked across diverse fronts: rare genetic diseases (Usher syndrome gene therapy), rare tumor diagnostics (sarcoma), and initial cardiotoxicity research. From 2020 onward, their focus consolidated sharply around two pillars — cardio-oncology (protecting hearts during cancer treatment) and data-driven precision medicine, including real-world data standardization and omics-based approaches to kidney and cardiovascular disease. The shift signals a move from broad clinical participation toward becoming a specialist hub where oncology and cardiology intersect.

IIS-FJD is converging on the cardio-oncology niche — expect them to seek partners in cardiac imaging, biomarker development, and AI-driven clinical decision tools for managing cancer patients with heart risks.

How they like to work

IIS-FJD operates primarily as a clinical partner within large European consortia (133 unique partners across 33 countries), contributing patient cohorts, clinical trial expertise, and disease-specific knowledge. They have coordinated two projects (SELNET and PRECISMEDLYM), both in rare/aggressive cancers where their clinical datasets gave them a leadership position. Their high partner diversity and low repeat-collaboration rate suggest they are sought after as a specialist contributor rather than building a fixed alliance network.

With 133 unique consortium partners spanning 33 countries, IIS-FJD has an exceptionally broad European network for its size. Their coordinator projects (SELNET) extended collaboration into Latin America, giving them unusual geographic reach for a Spanish clinical institute.

What sets them apart

IIS-FJD sits at the rare intersection of oncology and cardiology within a hospital-based research setting, giving them direct access to patient populations that most research institutes cannot match. Their coordination of both SELNET (sarcoma, European-Latin American network) and PRECISMEDLYM (lymphoma precision medicine) shows they can lead international clinical networks, not just participate. For consortium builders, their value is clinical trial infrastructure plus real patient data in cardiovascular and cancer domains — the kind of partner that turns a research proposal into a credible clinical validation plan.

Highlights from their portfolio

• SELNET
  Coordinated by IIS-FJD with EUR 567K funding, this project built a European-Latin American clinical network for sarcoma — their largest leadership role.
• RESILIENCE
  Their highest-funded project (EUR 637K), testing remote ischemic conditioning to protect lymphoma patients' hearts during anthracycline chemotherapy — a direct cardio-oncology application.
• RITA-MI 2
  A phase 2 clinical trial repurposing the cancer drug rituximab for heart attack patients — an unconventional drug repurposing approach bridging oncology and cardiology.